Peter Robert Rose

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 7 CIPO patents and 1 EPO patent. Top assignee: Pfizer Corporation. Active years: 1999-2024.

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 72.2

CIPO Patents = 7

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 37(Granted Patents)

Location History:

Ledyard, CT (US) (1999 - 2015)
Uncasville, CT (US) (2022)

Company Filing History:

18 out of 4,486

Pfizer Corporation

patents

Years Active: 1999-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116368 - Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto (2024-10-15),

2. 11299500 - Crystalline form of lorlatinib free base hydrate (2022-04-12),

3. 9056831 - Process for forming amorphous atorvastatin (2015-06-16),

4. 8258315 - Process for forming amorphous atorvastatin (2012-09-04),

5. 8026376 - Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1) (2011-09-27),

6. 7285686 - Process for the preparation of 1,3-substituted indenes (2007-10-23),

7. 7265119 - [object Object] (2007-09-04),

8. 6890927 - Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof (2005-05-10),

9. 6787549 - Citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof (2004-09-07),

10. 6696574 - Processes and intermediates for preparing glycogen phosphorylase inhibitors (2004-02-24),

11. 6683106 - N-(indole-2-carbonyl)-b-alaninamide crystal forms (2004-01-27),

12. 6673929 - Process for preparing growth hormone secretagogues (2004-01-06),

13. 6573383 - Preparation of anhydrous CETP inhibitor (2003-06-03),

14. 6541634 - Process for preparing growth hormone secretagogues (2003-04-01),

15. 6387925 - Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions (2002-05-14),

Title: Peter Robert Rose: Pioneering Innovations in Pharmaceuticals

Introduction:

Peter Robert Rose, a distinguished inventor in the field of pharmaceuticals, hails from Ledyard, CT (US) with an impressive portfolio of 17 patents. His groundbreaking work has significantly contributed to advancements in the treatment of diseases, particularly cancer.

Latest Patents:

Among his latest patents is the "Crystalline form of lorlatinib free base hydrate," which revolutionizes the pharmaceutical industry with its application in the treatment of abnormal cell growth like cancer. Additionally, his patented process for forming amorphous atorvastatin showcases his expertise in developing innovative solutions for medication delivery and efficacy.

Career Highlights:

Peter Robert Rose is an invaluable asset to Pfizer Corporation, where he channels his creativity and expertise to drive forward-thinking research and development initiatives. His dedication to pushing boundaries in pharmaceutical innovation has led to the successful commercialization of several groundbreaking products.

Collaborations:

Throughout his career, Peter Robert Rose has collaborated closely with esteemed colleagues such as Frank R Busch and Glenn R Williams. Together, they have formed a formidable team that consistently produces cutting-edge solutions that improve patient outcomes and quality of life.

Conclusion:

In conclusion, Peter Robert Rose exemplifies the epitome of an inventive mind dedicated to revolutionizing the pharmaceutical landscape. His relentless pursuit of excellence and his collaborative spirit continue to inspire the next generation of innovators in the field.